Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies
M Moradi, A Mousavi, Z Emamgholipour… - European Journal of …, 2023 - Elsevier
Angiogenesis, the formation of new blood vessels from the existing vasculature, is pivotal in
the migration, growth, and differentiation of endothelial cells in normal physiological …
the migration, growth, and differentiation of endothelial cells in normal physiological …
Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors
In our attempt to discover effective anticancer agents, three series of novel quinazoline-
based compounds have been designed, synthesized and tested as VEGFR-2 inhibitors. Five …
based compounds have been designed, synthesized and tested as VEGFR-2 inhibitors. Five …
Discovery of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation
IH Eissa, AGA El-Helby, HA Mahdy, MM Khalifa… - Bioorganic …, 2020 - Elsevier
Sixteen novel quinazoline-based derivatives were designed and synthesized via
modification of the VEGFR-2 reported inhibitor 7 in order to increase the binding affinity of …
modification of the VEGFR-2 reported inhibitor 7 in order to increase the binding affinity of …
Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: Design, synthesis, antiproliferative, docking and MD simulation studies
A new set of quinoline and isatine derivatives were synthesized as antiangiogenic VEGFR-2
inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit …
inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit …
[HTML][HTML] Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies
EB Elkaeed, RG Yousef, MM Khalifa, A Ibrahim… - Molecules, 2022 - mdpi.com
Four new nicotinamide-based derivatives were designed as antiangiogenic VEGFR-2
inhibitors. The congeners were synthesized possessing the pharmacophoric essential …
inhibitors. The congeners were synthesized possessing the pharmacophoric essential …
Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma
A series of new VEGFR-2 inhibitors were designed, synthesized and evaluated for their anti-
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
Design, synthesis and molecular modeling of new quinazolin-4 (3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation
AE Abdallah, SI Eissa, MMS Al Ward, RR Mabrouk… - Bioorganic …, 2021 - Elsevier
Globally cancer is the second leading cause of death. So that this work is an attempt to
develop new effective anti-cancer agents. In line with pharmacophoric features of VEGFR-2 …
develop new effective anti-cancer agents. In line with pharmacophoric features of VEGFR-2 …
Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase
SUF Rizvi, HL Siddiqui, M Nisar, N Khan… - Bioorganic & medicinal …, 2012 - Elsevier
Vascular endothelial growth factor Receptor-2 (VEGFR-2) kinase inhibition is one of the well
established strategies to promptly tackle tumor growth by suppression of angiogenesis. In …
established strategies to promptly tackle tumor growth by suppression of angiogenesis. In …
Identification of new [1, 2, 4] triazolo [4, 3-a] quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies
Tumor angiogenesis is mainly regulated by VEGFR-2. In this study, a new series of [1, 2, 4]
triazolo [4, 3-a] quinoxaline based-derivatives has been designed and synthesized to …
triazolo [4, 3-a] quinoxaline based-derivatives has been designed and synthesized to …
An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review
Cancer is one of the leading causes of death. Globally a huge number of deaths and new
incidences are reported annually. Heterocyclic compounds have been proved to be very …
incidences are reported annually. Heterocyclic compounds have been proved to be very …